MicroFluidic Systems HOME CORE AREAS ABOUT US CAREERS ARCHIVE NEWS & EVENTS CONTACT US
NEWS
MicroFluidic Systems (MFS) specializes in molecular diagnostic systems for the detection of airborne biological threats and rapid medical testing. The company, founded in 2001, focuses on homeland security and healthcare applications, and is a wholly owned subsidiary of PositiveID Corporation (OTCBB: PSID).

MFS' primary products are its M-BAND and DragonFly systems. MFS also markets a variety of assays for rapid and accurate biological detection of viruses, bacteria and other toxins. The company's M-BAND, Microfluidics-based Bioagent Autonomous Networked Detector, runs autonomously for 30 days, continuously analyzing air samples to detect bacteria, viruses and toxins, with results in as little as two hours. Results from individual instruments are reported via a secure wireless network in real time to give an accurate and up-to-date status for instruments in the field.

The company's Dragonfly technology is a miniaturized version of M-BAND, and can be used in a healthcare setting or in the field. Dragonfly's microfluidic cartridges for biological sample processing and detection have been demonstrated effective for environmental bacteria, biothreat agents, clinical samples, antibiotic-resistant bacteria and forensic applications. PositiveID develops innovative tools and technologies, focused on diabetes management and biological detection systems, for a better quality of life.
May 16, 2012

PositiveID Corporation's MicroFluidic Systems Subsidiary Makes Significant Progress in Preparation for $3 Billion BioWatch Procurement
more

May 14, 2012

PositiveID Corporation Collaborates With the University of Nevada to Complete Development of Its Biodosimetry Cartridge for Measuring Radiation
more

April 2, 2012

PositiveID Corporation Announces First Quarter 2012 Accomplishments: Positions Itself for $3 Billion BioWatch Contract and Advances the Development of Its Diabetes Management Products
more

March 28, 2012

PositiveID Corporation Receives Nucleic Acids From the CDC Influenza Division to Develop a Diagnostic Assay to Detect H5N1 Avian Flu
more